UY25992A1 - Procedimiento para preparar inhibidores de tace (enzima conversora del factor alfa de necrosis tumoral) - Google Patents
Procedimiento para preparar inhibidores de tace (enzima conversora del factor alfa de necrosis tumoral)Info
- Publication number
- UY25992A1 UY25992A1 UY25992A UY25992A UY25992A1 UY 25992 A1 UY25992 A1 UY 25992A1 UY 25992 A UY25992 A UY 25992A UY 25992 A UY25992 A UY 25992A UY 25992 A1 UY25992 A1 UY 25992A1
- Authority
- UY
- Uruguay
- Prior art keywords
- sup
- conversing
- enzyme
- preparing
- procedure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Procedimiento para preparar derivados de hidroxiamida heterocíclicos de fórmula (I) en donde: X es O, S, SO, SO2 o NR7 (R7 es H o alquilo); R1, R2, R3, R4, R5, Y R6 se seleccionan del grupo integrado por hidrógeno, hidroxi, ciano, alquilo, alquenilo, alquinilo, alquilamino, tioalquilo, alcoxi, perfluoroalquilo, arilo, heteroarilo, arilamino, tioarilo, ariloxi, piperidilo, tioacilo, y CO2H; Q es ariloalcoxiarilo, ariloalcoxiheteroarilo, heteroariloalcoxiarilo, o heteroariloalcoxiheteroarilo; y a composiciones farmacéuticas que comprenden tales derivados y al uso de tales derivados en el tratamiento de la artritis, cáncer y otras enfermedades que implican una producción / liberación no regulada de reprolisinas como alfa-TNF (factor alfa de necrosis tumoral) y otras enfermedades caracterizadas por actividad de metaloproteinasas de la matriz. Además, los compuestos de la presente invención se pueden usar en terapia de combinación con fármacos antiinflamatorios no esteroides (AINEs), inhibidores de la COX-2 y analgésicos convencionales, y en el tratamiento del cáncer, en combinación con fármacos citotóxicos como adriamicina, daunomicina, cisplatino, etopósido, taxol, taxótero y otros alcaloides como vincristina. Ej. no limitante: hidroxiamida del ácido (2S,3S) 4-[4-(3,5-difluorobenciloxi)-bencenosulfonil]-2-metiltiomorfolin-3-carboxílico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9625698P | 1998-08-12 | 1998-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY25992A1 true UY25992A1 (es) | 2000-03-31 |
Family
ID=22256553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY25992A UY25992A1 (es) | 1998-08-12 | 2000-01-28 | Procedimiento para preparar inhibidores de tace (enzima conversora del factor alfa de necrosis tumoral) |
Country Status (15)
Country | Link |
---|---|
US (2) | US20030181441A1 (es) |
EP (1) | EP1104412B1 (es) |
JP (1) | JP3623448B2 (es) |
AT (1) | ATE297908T1 (es) |
AU (1) | AU4925099A (es) |
BR (1) | BR9912944A (es) |
CA (1) | CA2340182A1 (es) |
DE (1) | DE69925840T2 (es) |
ES (1) | ES2242402T3 (es) |
GT (1) | GT199900132A (es) |
MA (1) | MA26674A1 (es) |
PA (1) | PA8479901A1 (es) |
TN (1) | TNSN99157A1 (es) |
UY (1) | UY25992A1 (es) |
WO (1) | WO2000009492A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6406901B1 (en) | 1995-06-08 | 2002-06-18 | Immunex Corporation | TNF-a converting enzyme |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
EP1081137A1 (en) | 1999-08-12 | 2001-03-07 | Pfizer Products Inc. | Selective inhibitors of aggrecanase in osteoarthritis treatment |
GB9922825D0 (en) * | 1999-09-25 | 1999-11-24 | Smithkline Beecham Biolog | Medical use |
GB0004531D0 (en) * | 2000-02-25 | 2000-04-19 | Richards Andrew J M | The treatment of respiratory diseases |
US6458822B2 (en) | 2000-03-13 | 2002-10-01 | Pfizer Inc. | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases |
EP1138680A1 (en) * | 2000-03-29 | 2001-10-04 | Pfizer Products Inc. | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors |
MXPA01013326A (es) | 2001-02-14 | 2002-08-26 | Warner Lambert Co | Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz. |
US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7732451B2 (en) | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
AU2002331064B2 (en) | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
AUPR726201A0 (en) * | 2001-08-24 | 2001-09-20 | Fujisawa Pharmaceutical Co., Ltd. | New use of a cyclic compound |
WO2003106381A2 (en) | 2002-06-12 | 2003-12-24 | Exelixis, Inc. | Human adam-10 inhibitors |
WO2005021489A2 (en) | 2002-12-23 | 2005-03-10 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
EA009121B1 (ru) | 2003-04-09 | 2007-10-26 | Миллениум Фармасьютикалз, Инк. | Бета-карболины, применяемые для лечения воспалительных заболеваний |
US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
JP2007532582A (ja) | 2004-04-09 | 2007-11-15 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症性疾患の処置に有用なβ−カルボリン |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
WO2007016597A2 (en) * | 2005-07-29 | 2007-02-08 | The Regents Of The University Of California | Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy |
US20100226922A1 (en) * | 2006-06-08 | 2010-09-09 | Dorothea Maetzel | Specific protease inhibitors and their use in cancer therapy |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
IT1404729B1 (it) * | 2011-01-27 | 2013-11-29 | Univ Pisa | Inibitori altamente selettivi dell'attivita' di adams |
CN103998435A (zh) * | 2011-10-04 | 2014-08-20 | 法国国家健康医疗研究院 | 新型细胞凋亡诱导化合物 |
CN111500721B (zh) * | 2020-04-20 | 2022-11-29 | 青岛大学附属医院 | Tace在腹主动脉瘤腔内修复术后内漏诊断中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5753653A (en) * | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
CN1542002A (zh) * | 1995-12-08 | 2004-11-03 | ������ҩ������˾ | 金属蛋白酶抑制剂,含有它们的药物组合物和其药物用途,其制备方法和中间体 |
NZ334252A (en) * | 1996-08-28 | 2000-11-24 | Procter & Gamble | Heterocyclic metalloprotease inhibitors |
EP0948489A1 (en) * | 1996-12-17 | 1999-10-13 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine compounds as inhibitors of mmp or tnf |
HUP0000657A3 (en) * | 1997-02-11 | 2000-10-30 | Pfizer | N-arylsulfonyl-piperidine, -morpholine hydroxamic acid derivatives and pharmaceutical compositions containing them |
EP1081137A1 (en) * | 1999-08-12 | 2001-03-07 | Pfizer Products Inc. | Selective inhibitors of aggrecanase in osteoarthritis treatment |
-
1999
- 1999-08-05 WO PCT/IB1999/001392 patent/WO2000009492A1/en active IP Right Grant
- 1999-08-05 BR BR9912944-2A patent/BR9912944A/pt not_active IP Right Cessation
- 1999-08-05 DE DE69925840T patent/DE69925840T2/de not_active Expired - Fee Related
- 1999-08-05 ES ES99933079T patent/ES2242402T3/es not_active Expired - Lifetime
- 1999-08-05 AT AT99933079T patent/ATE297908T1/de not_active IP Right Cessation
- 1999-08-05 AU AU49250/99A patent/AU4925099A/en not_active Abandoned
- 1999-08-05 JP JP2000564944A patent/JP3623448B2/ja not_active Expired - Fee Related
- 1999-08-05 CA CA002340182A patent/CA2340182A1/en not_active Abandoned
- 1999-08-05 EP EP99933079A patent/EP1104412B1/en not_active Expired - Lifetime
- 1999-08-06 PA PA19998479901A patent/PA8479901A1/es unknown
- 1999-08-11 TN TNTNSN99157A patent/TNSN99157A1/fr unknown
- 1999-08-11 MA MA25729A patent/MA26674A1/fr unknown
- 1999-08-12 GT GT199900132A patent/GT199900132A/es unknown
- 1999-08-12 US US09/373,182 patent/US20030181441A1/en not_active Abandoned
-
2000
- 2000-01-28 UY UY25992A patent/UY25992A1/es not_active Application Discontinuation
-
2005
- 2005-05-03 US US11/120,846 patent/US20050215549A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PA8479901A1 (es) | 2000-05-24 |
US20030181441A1 (en) | 2003-09-25 |
WO2000009492A1 (en) | 2000-02-24 |
ES2242402T3 (es) | 2005-11-01 |
AU4925099A (en) | 2000-03-06 |
JP3623448B2 (ja) | 2005-02-23 |
JP2003526604A (ja) | 2003-09-09 |
DE69925840D1 (de) | 2005-07-21 |
EP1104412A1 (en) | 2001-06-06 |
DE69925840T2 (de) | 2006-05-04 |
TNSN99157A1 (fr) | 2005-11-10 |
GT199900132A (es) | 2001-02-02 |
BR9912944A (pt) | 2001-05-08 |
ATE297908T1 (de) | 2005-07-15 |
EP1104412B1 (en) | 2005-06-15 |
CA2340182A1 (en) | 2000-02-24 |
US20050215549A1 (en) | 2005-09-29 |
MA26674A1 (fr) | 2004-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY25992A1 (es) | Procedimiento para preparar inhibidores de tace (enzima conversora del factor alfa de necrosis tumoral) | |
YU5201A (sh) | Derivati hidroksipipekolathidroksamske kiseline kao inhibitori mmp | |
BR0101241A (pt) | ácidos hidroxâmicos gem substituìdos | |
TR199901849T2 (xx) | Arils�lfonilamino hidroksamik asit t�revleri. | |
PT1292594E (pt) | Derivados de quinazolina para o tratamento de tumores | |
BRPI0413452A (pt) | composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv | |
EA199900036A1 (ru) | Ингибиторы металлопротеаз матрикса на основе фосфинатов, фармацевтическая композиция, способ лечения | |
IS6329A (is) | Lyf til að meðhöndla illkynja æxli | |
AU2002352708A1 (en) | Cytotoxic agents | |
PT1181286E (pt) | Hidroxamidas de acido 3-(arilsulfonilamino)-tetrahidropirano-3-carboxilico | |
ATE251618T1 (de) | 3-(arylsulfonylamino)-tetrahydrofuran-3- carbonsäure-hydroxamide | |
AU3282300A (en) | Molecules for the treatment and diagnosis of tumors | |
ECSP993100A (es) | Derivados de acido hidroxi - pipecolato hidroxamico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20100518 |